---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-152050"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2026-04-13T23:59:59+00:00"
generated_at: "2026-05-15T06:36:13.041245+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology appoints Jeff Knight as Chief Development and Operating Officer

## Summary
- Jeff Knight, former CDOO at Crinetics, appointed effective April 13, 2026; role includes clinical development and operations.
- Compensation: $565k base salary, 40% annual target bonus, and stock option for 800k shares under 2025 Inducement Plan.
- Knight brings 30+ years experience; previously at Poseida, Halozyme, Amgen, and Genentech.
- Company highlights upcoming catalysts for evorpacept and ALX2004 programs in next 12-18 months.

## SEC filing metadata
- accession: 0001193125-26-152050
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2026-04-13T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000119312526152050/0001193125-26-152050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000119312526152050/alxo-20260413.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-152050
- JSON: https://secwatch.observer/filing/0001193125-26-152050.json
- Plain text: https://secwatch.observer/filing/0001193125-26-152050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.